Key Highlights:

  • Estrella Immunopharma shares rose 11.24% to $0.8085 on Friday, October 23, 2026.
  • The company has not announced a catalyst for the session; the latest releases are dated October 14 and 15.
  • STARLIGHT-1 now has five clinical sites after Intermountain Health LDS Hospital was activated on October 14.
  • Cash was $0.1 million on June 30, 2026, against a working capital deficit of $7.4 million.
  • Accrued milestone liabilities owed to a partner total $8.3 million.

What Is Behind the 11% Jump in Estrella Immunopharma Stock?

Estrella Immunopharma (NASDAQ:ESLA) shares rose 11.24% to $0.8085 on Friday, October 23, 2026, from a prior close of about $0.7268 (calculated). The company has not announced a catalyst for the session, and no filing or release is dated October 23.

The most recent company news came in mid-October. On October 14, Estrella announced that Intermountain Health LDS Hospital became the fifth clinical site for its STARLIGHT-1 trial, and on October 15 it said the first patient had been treated with two infusions of EB103 in the dose-expansion phase.

Estrella is a clinical-stage biotechnology company developing cell therapies for blood cancers. Its main program, EB103, is a CD19-redirected T-cell therapy built on the ARTEMIS platform.

STARLIGHT-1 Trial: How Far Along Is the EB103 Program?

STARLIGHT-1 is a Phase I/II, multi-center, open-label study of EB103 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The registry identifier is NCT06343311.

The first patient entered the dose-expansion phase on July 24, 2026. Active sites included UC Davis Comprehensive Cancer Center and Baylor Scott & White Research Institute before Intermountain was added.

The company has said that at the six-month assessment of evaluable Phase I patients without central nervous system involvement, every patient who reached a complete response remained in complete response. It did not publish patient counts or response rates in that statement.

Data from the expansion cohort are intended to inform the strategy for a pivotal trial. The company has not given dates for those readouts.

Balance Sheet Risk: How Much Cash Does Estrella Have?

The balance sheet is the main caution in the filings. A summary of the quarterly report for the period ended June 30, 2026, showed cash and cash equivalents of $0.1 million and a working capital deficit of $7.4 million.

Accrued milestone liabilities of $8.3 million are owed to Eureka Therapeutics. The same summary listed $687,000 of derivative liabilities tied to share true-up obligations.

Those figures indicate the company depends on new financing to continue trial activity. The company did not announce a financing alongside the October trial updates, and net loss and market capitalisation figures were not available from the sources used here.

At $0.8085, the shares trade below $1, which is the level that often draws attention to small-cap biotechs. The company has not linked the move to any event.

What to Watch Next: Can Estrella Fund the Expansion Cohort?

The takeaway is that clinical activity is advancing while liquidity remains the open question. No dated event has been announced; investors can look for third-quarter financial statements, which have no confirmed date, and for any expansion-cohort data or financing disclosure.

The company has not announced a catalyst for the session. Its latest news was a fifth trial site on October 14 and a first expansion patient with two infusions on October 15.

It is a Phase I/II study of EB103, a CD19-directed T-cell therapy, in adults with relapsed or refractory B-cell non-Hodgkin lymphoma.

Cash and cash equivalents were $0.1 million, with a working capital deficit of $7.4 million.